These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 37614103)
1. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants. Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103 [TBL] [Abstract][Full Text] [Related]
2. Optimizing the use of Paxlovid in clinical practice. McCarthy MW Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515 [TBL] [Abstract][Full Text] [Related]
3. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987 [TBL] [Abstract][Full Text] [Related]
4. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997 [TBL] [Abstract][Full Text] [Related]
5. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195 [TBL] [Abstract][Full Text] [Related]
7. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients. Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial. Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022. Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674 [TBL] [Abstract][Full Text] [Related]
11. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
12. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743 [TBL] [Abstract][Full Text] [Related]
13. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related]
14. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM; N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054 [TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir Plus Ritonavir: First Approval. Lamb YN Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258 [TBL] [Abstract][Full Text] [Related]
16. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754 [TBL] [Abstract][Full Text] [Related]
17. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants. Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224 [TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893 [TBL] [Abstract][Full Text] [Related]
19. Simnotrelvir as a potential treatment for COVID-19. McCarthy MW Expert Opin Pharmacother; 2024 Feb; 25(3):233-237. PubMed ID: 38393345 [TBL] [Abstract][Full Text] [Related]
20. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Hung YP; Lee JC; Chiu CW; Lee CC; Tsai PJ; Hsu IL; Ko WC Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]